Stocks · News reference
Ardent Health Lowers FY2026 GAAP EPS Guidance from $0.90-$1.27 to $0.78-$1.15 vs $1.09 Est; Affirms FY2026 Sales Guidance of $6.400B-$6.700B vs $6.441B Est
Ardent Health (NYSE:ARDT) lowers FY2026 GAAP EPS guidance from $0.90-$1.27 to $0.78-$1.15 vs $1.09 analyst estimate. Affirms FY2026 sales outlook from $6.400 billion-$6.700 billion to $6.400 billion-$6.700 billion vs
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11
BMO Capital analyst Sean Dodge initiates coverage on Ardent Health (NYSE:ARDT) with a Market Perform rating and announces Price Target of $11.
8-K filing — Ardent Health, Inc. (ARDT)
Filed: 2026-09-04 AccNo: 0001628280-26-060735 Size: 394 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13
RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.